Education
About Us
Working with TipRanks
Follow Us
Viatris, Inc. (DE:VIA)
:VIA
VIA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€9.30 - €12.86
Previous CloseN/A
Volume947.00
Average Volume (3M)2.62K
Market Cap
€12.76B
Enterprise Value€27.98B
Total Cash (Recent Filing)$388.10M
Total Debt (Recent Filing)$13.82B
Price to Earnings (P/E)―
Beta0.24
Next Earnings
Feb 27, 2025EPS Estimate
0.54Next Dividend Ex-Date
Mar 10, 2025Dividend Yield4.27%
Share Statistics
EPS (TTM)-0.69
Shares Outstanding1,193,592,900
10 Day Avg. Volume1,724
30 Day Avg. Volume2,616
Standard Deviation0.09
R-Squared0.06
Alpha0.00527
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.89
Price to Cash Flow (P/CF)4.10
P/FCF Ratio3.80
Enterprise Value/Market Cap2.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.35
Enterprise Value/Ebitda11.13
Forecast
1Y Price Target
€13.78Price Target Upside27.39% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Viatris News
PremiumCompany Announcements
Viatris Reports Strong 2024 Financial Results
PremiumCompany Announcements
Viatris, Inc. Earnings Call: Balancing Growth and Challenges
---
Bulls Say, Bears Say
Bulls Say
Earnings GuidanceViatris is expected to benefit from a strong guide into 2025, which could act as a catalyst for its shares.
Product PipelineThe company expects significant new product revenues, supported by an estimated 140 filings annually, which contribute to incremental growth.
Share BuybacksViatris plans to be more aggressive with buybacks, supported by its financial flexibility and a substantial amount of free cash flow.
Bears Say
Growth ProspectsViatris has limited potential for upward revisions and lacks clinical catalysts for 2025, which affects its growth prospects.
Market PerformanceAnalyst reiterates an Underperform rating for Viatris, suggesting the shares are likely to lag peers and the broader market.
Sales And EBITDA DeclineThe company faces sequential headwinds in the fourth quarter, with expected declines in sales and EBITDA.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.16% Insiders
23.34% Mutual Funds
20.99% Other Institutional Investors
25.94% Public Companies and Individual Investors
VIA FAQ
What was Viatris, Inc.’s price range in the past 12 months?
Viatris, Inc. lowest stock price was €9.30 and its highest was €12.86 in the past 12 months.
What is Viatris, Inc.’s market cap?
Viatris, Inc.’s market cap is €12.76B.
When is Viatris, Inc.’s upcoming earnings report date?
Viatris, Inc.’s upcoming earnings report date is Feb 27, 2025 which is yesterday.
How were Viatris, Inc.’s earnings last quarter?
Viatris, Inc. released its earnings results on Feb 27, 2025. The company reported €0.52 earnings per share for the quarter, missing the consensus estimate of €0.551 by -€0.031.
Is Viatris, Inc. overvalued?
According to Wall Street analysts Viatris, Inc.’s price is currently Undervalued.
Does Viatris, Inc. pay dividends?
Viatris, Inc. pays a Quarterly dividend of €0.113 which represents an annual dividend yield of 4.27%. See more information on Viatris, Inc. dividends here
What is Viatris, Inc.’s EPS estimate?
Viatris, Inc.’s EPS estimate is 0.54.
How many shares outstanding does Viatris, Inc. have?
Viatris, Inc. has 1,193,592,900 shares outstanding.
What happened to Viatris, Inc.’s price movement after its last earnings report?
Viatris, Inc. reported an EPS of €0.52 in its last earnings report, missing expectations of €0.551. Following the earnings report the stock price went down -16.486%.
Which hedge fund is a major shareholder of Viatris, Inc.?
Currently, no hedge funds are holding shares in DE:VIA
---
Viatris Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.78 (27.39% Upside)
€13.78 (27.39% Upside)
Blogger Sentiment
Bullish
DE:VIA Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $346.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.00%
12-Months-Change
Fundamentals
Return on Equity
-4.35%
Trailing 12-Months
Asset Growth
-8.18%
Trailing 12-Months
Company Description
Viatris, Inc.
Viatris Inc. is a global healthcare company headquartered in Canonsburg, Pennsylvania. Formed in 2020 through the merger of Mylan and Pfizer’s Upjohn division, Viatris provides a wide range of medicines, including branded drugs, generics, biosimilars, and over-the-counter products. The company operates in over 165 countries and serves patients across numerous therapeutic areas, including infectious diseases, cardiovascular health, and oncology. Viatris also offers patient support programs and works with healthcare systems to address medical needs worldwide.
---
VIA Company Deck
---
VIA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
While Viatris reported growth in revenues and made significant strides in debt reduction and pipeline development, the Indore facility challenges pose a substantial negative impact on 2025 financials. The company is actively addressing these issues, but the overall sentiment is balanced with significant achievements and challenges.Read More>---
VIA Net sales Breakdown
60.12% Developed Markets
16.58% Emerging Markets
14.04% Greater China
9.26% JANZ
---
VIA Stock 12 Month Forecast
Average Price Target
€13.78
▲(27.39% Upside)
Technical Analysis
Bristol-Myers Squibb
―
GlaxoSmithKline
―
Johnson & Johnson
―
Merck & Company
―
Pfizer
―
Best Analysts Covering VIA
1 Year
1 Year Success Rate
8/20 ratings generated profit
1 Year Average Return
-3.43%
reiterated a sell rating 2 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 42.11% of your transactions generating a profit, with an average return of -3.43% per trade.
---